Efficacy of Cytokine Removal by Plasmadiafiltration Using a Selective Plasma Separator: In Vitro Sepsis Model

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 1, 2011, Pages 98-108

  Li, Mingxin ^a   Xue, Jun ^a   Liu, Junfeng ^a   Kuang, Dingwei ^a   Gu, Yong ^a   Lin, Shanyan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cytokine; Inflammation; Plasmadiafiltration; Sepsis; Sieving coefficient

Indexed keywords

ALBUMIN; BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PLASMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD FLOW VELOCITY; DIALYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUID FLOW; INFLAMMATION; PLASMAPHERESIS; PRIORITY JOURNAL; SEPSIS;

EID: 79251549816     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00850.x     Document Type: Article

References (33)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-91.
2. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78.
3. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest 2007;117:289-96.
4. Ziegler EJ, Fisher CJ Jr, Sprung CL etal. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-36.
5. Abraham E, Wunderink R, Silverman H etal. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
6. Honore PM, Jamez J, Wauthier M etal. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-7.
7. Cole L, Bellomo R, Journois D etal. High-volume haemofiltration in human septic shock. Intensive Care Med 2001;27:978-86.
8. Cornejo R, Downey P, Castro R etal. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713-22.
9. Uchino S, Bellomo R, Goldsmith D etal. Cytokine removal with a large pore cellulose triacetate filter: an ex vivo study. Int J Artif Organs 2002;25:27-32.
10. Morgera S, Klonower D, Rocktäschel J etal. TNF-αelimination with high cut-off haemofilters: a feasible clinical modality for septic patients. Nephrol Dial Transplant 2003;18:1361-9.
11. Morgera S, Slowinski T, Melzer C etal. Renal replacing therapy with high cut-off hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004;43:444-53.
12. Nakae H, Igarashi T, Tajimi K etal. A case report of hepatorenal syndrome treated with plasma diafiltration(selective plasma filtration with dialysis). Ther Apher Dial 2007;11:391-5.
13. Nakae H, Igarashi T, Tajimi K etal. A case report of pediatric fulminant hepatitis treated with plasma diafiltration. Ther Apher Dial 2008;12:329-32.
14. Mariano F, Fonsato V, Lanfranco G etal. Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant 2005;20:1116-26.
15. Kriegler M, Perez C, DeFay K etal. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45-53.
16. Dinarello CA. The interleukin-1 family: 10years of discovery. Faseb J 1994;8:1314-25.
17. Arend WP, Malyak M, Guthridge CJ etal. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
18. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Rev Immun 2006;6:595-601.
19. Smith KA. The interleukin 2 receptor. Annu Rev Cell Biol 1989;5:397-425.
20. van der Poll T, Keogh CV, Guirao X etal. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997;176:439-44.
21. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992;307:97-101.
22. Mocellin S, Panelli MC, Wang E etal. The dual role of IL-10. Trends 2004;24:36-43.
23. Wang HC, Zhu S, Zhou RR etal. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 2008;10:e32-56.
24. Oberholzer C, Oberholzer A, Clare-Salzler M etal. Apoptosis in sepsis:a new target for therapeutic exploration. FASEB J 2001;15:879-92.
25. Oberholzer A, Oberholzer C, Moldawer LL. Understangding the role of innate and acquired immunity. Shock 2001;16:83-96.
26. Hotchkiss RS, Karl JE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
27. Marshall JC. Clinical trials of mediator-directed therapy in sepsis:what have we learned? Intensive Care Med 2000;26(Suppl 1):S75-83.
28. Ronco C, Tetta C, Mariano F etal. Interpreting the mechanisms of continuous renal replacing therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
29. Ronco C, Bellomo R, Homel P etal. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospetcive randomised trial. Lancet 2000;356:26-30.
30. Ronco C, Bonello M, Bordoni V etal. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004;22:164-74.
31. Piccinni P, Dan M, Barbacini S etal. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006;32:80-6.
32. Lonnemann G, Behme TC, Lenzner B etal. Permeability of dialyzer membranes to TNFα-inducing substances derived from water bacteria. Kidney Int 1992;42:61-8.
33. Kuschert GS, Coulin F, Power CA etal. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-68.